Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지

Oncolytic Vaccinia Virus Expressing 4-1BBL Inhibits Tumor Growth by Increasing CD8+ T Cells in B16F10 Tumor Model

  • Lee, Na-Kyung (Department of Biomedical Laboratory Science, Soon Chun Hyang University) ;
  • Kim, Hong-Sung (Department of Biomedical Laboratory Science, Korea Nazarene University)
  • Received : 2012.07.18
  • Accepted : 2012.09.15
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Oncolytic viral vectors have shown good candidates for cancer treatment but have many limitations. To improve the therapeutic potential of oncolytic vaccinia virus, we developed a recombinant vaccinia virus expressing the 4-1BBL co-stimulatory molecule or CCL21. 4-1BBL and CCL21 expression was identified by FACS analysis and immunoblotting. rV-4-1BBL vaccination shows significant tumor regression compared to rV-LacZ, but rV-CCL21 shows rapid tumor growth compared to rV-LacZ in the poorly immunogenic B16 murine melanoma model. 4-1BBL expression resulted in the increase of the number of CD8+ T cells and especially the increase of effector (CD62L-CD44+) CD8+ T cells. These data suggest 4-1BBL may be the potential target for enhancement of tumor immunotherapy.

Keywords

References

  1. Applebaum J, Reynolds S, Knispel J, Oratz R, Shapiro R, Bystryn JC. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J Natl Cancer Inst. 1998. 90: 146-149. https://doi.org/10.1093/jnci/90.2.146
  2. John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 2012. 72: 1651-1660. https://doi.org/10.1158/0008-5472.CAN-11-2788
  3. Kalbacova M, Spisakova M, Liskova J, Melkova Z. Lytic infection with vaccinia virus activates caspases in a Bcl-2-inhibitable manner. Virus Res. 2008. 135: 53-63. https://doi.org/10.1016/j.virusres.2008.02.007
  4. Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, Schlom J, Hesdorffer C. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther. 2006. 17: 239-244. https://doi.org/10.1089/hum.2006.17.239
  5. Kaufman HL, Deraffele D, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Horig H, Marincola FM. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005. 115: 1903-1912. https://doi.org/10.1172/JCI24624
  6. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009. 9: 64-71. https://doi.org/10.1038/nrc2545
  7. Kober J, Leitner J, Klauser C, Woitek R, Majdic O, Stockl J, Herndler-Brandstetter D, Grubeck-Loebenstein B, Reipert BM, Pickl WF, Pfistershammer K, Steinberger P. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol. 2008. 38: 2678-2688. https://doi.org/10.1002/eji.200838250
  8. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 2006. 24: 4975-4986. https://doi.org/10.1016/j.vaccine.2006.03.042
  9. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL. Systemic cancer therapy with a tumorselective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001. 61: 8751-8757.
  10. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 costimulatory pathway. Eur J Immunol. 1998. 28: 1116-1121. https://doi.org/10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A
  11. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumors. Nat Rev Cancer. 2005. 5: 965-976.
  12. Schmidt FI, Bleck CK, Mercer J. Poxvirus host cell entry. Curr Opin Virol. 2012. 2: 20-27. https://doi.org/10.1016/j.coviro.2011.11.007
  13. Serghides L, Bukczynski J, Wen T, Wang C, Routy JP, Boulassel MR, Sekaly RP, Ostrowski M, Bernard NF, Watts TH. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol. 2005. 175: 6368-6377.
  14. Sharma S, Yang SK, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM, Dubinett SM. SLC/CCL21-mediated anti-tumor responses require IFN, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer. 2003. 2: 22-27. https://doi.org/10.1186/1476-4598-2-22
  15. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007. 13: 1440-1449. https://doi.org/10.1038/nm1676
  16. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest. 2007. 117: 3350-3358. https://doi.org/10.1172/JCI32727
  17. van der Bruggen P, Traversari C, Chomez P, Lurguin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991. 254: 1643-1647. https://doi.org/10.1126/science.1840703
  18. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002. 109: 651-659.
  19. Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther. 2005. 12: 1526-1533. https://doi.org/10.1038/sj.gt.3302556
  20. Yi KH, Nechushtan H, Bowers WJ, Walker GR, Zhang Y, Pham DG, Podack ER, Federoff HJ, Tolba KA, Rosenblatt JD. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Res. 2007. 67: 10027-10037. https://doi.org/10.1158/0008-5472.CAN-06-2391
  21. Zhao Y, Croft M. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells. Immunol Lett. 2012. 141: 220-226. https://doi.org/10.1016/j.imlet.2011.10.008